SwRI and Texas Biomed are collaborating to test AI-identified antiviral compounds against Ebola virus, targeting the Bundibugyo species as the strain resurfaces in the Democratic Republic of Congo. SwRI said it has identified nearly two dozen candidate compounds designed to interact with Bundibugyo. In parallel, animal studies of a newly designed vaccine against Bundibugyo Ebola are underway in the U.S. and U.K., with Serum Institute of India positioned to manufacture vaccine material for clinical trials if preclinical results support progression. The reporting also indicated that an adaptive trial protocol for antivirals has been agreed for field evaluation. Separately, U.S. HHS issued emergency immunity to support the use of favipiravir as a medical countermeasure for hantavirus pulmonary syndrome, underscoring how regulatory and legal frameworks are being used to accelerate access during emerging public health threats. For biotech stakeholders, the Ebola-focused sequence highlights a fast-moving pipeline pattern: AI-enabled discovery feeding preclinical evaluation, while manufacturing readiness and adaptive trial designs aim to compress time to evidence generation.